Amgen Tries To Force Sandoz Biosimilar Disclosures
Amgen Inc. on Tuesday urged a California federal judge to find that Sandoz Inc. flouted the Affordable Care Act by withholding information on its biosimilar version of Neupogen, setting the stage...To view the full article, register now.
Already a subscriber? Click here to view full article